NCT04430738 2026-02-24Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersSeagen Inc.Phase 2 Active not recruiting40 enrolled 67 charts
NCT00478140 2019-08-20Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by SurgeryNational Cancer Institute (NCI)Phase 2 Terminated4 enrolled 6 charts